OXFORD GASTRO-OESOPHAGEAL SYMPOSIUM

He is the National Lead in Ireland for Oesophageal and Gastric cancer. He
is Cancer Clinical Lead at the Trinity St James’s Cancer Institute. He is President of the Irish Society of
Clinical Nutrition and Metabolism (IRSPEN). He is President of the European Society of Diseases of
the Oesophagus (ESDE). He is on the Editorial Board of the European Surgical Association (ESA). He is
on the Accreditation and Designation Board of the Organisation of European Cancer Institutes (OECI).
Professor Reynolds has published widely in predominantly cancer research, with approximately 500
peer-reviewed publications, and over €6m research grant income.

Research is focused on
outcomes after surgery for gastric and oesophageal cancer and clinical studies on neoadjuvant
treatment for oesophageal and gastric cancer. Dr. Wijnhoven is editor for BJS (British Journal of
Surgery) since 2014. He has authored and co-authored over 350 articles in national and international
peer-reviewed journals.

His main clinical and scientific interests are gastric and oesophageal cancer with particular focus on minimally invasive surgical techniques, adjunct oncological therapies, new therapies for peritoneal metastases and management of surgical complications. Dr Nilsson is the past President of the European Society for Diseases of the Esophagus, the Swedish Society of Upper Abdominal Surgery and currently the
Chairman of the Swedish National Registry for Gastric and Esophageal Cancer. Dr Nilsson has a strong focus on multidisciplinary collaboration in cancer care and research and is a faculty member of the upper gastrointestinal group of the European Society for Medical Oncology (ESMO) and a member of the European Organization for Research and Treatment of Cancer (EORTC) gastrointestinal group. Dr
Nilsson is Editor-in Chief of the journal Diseases of the Esophagus.

He is director of the Division of Thoracic and Upper Gastrointestinal Surgery and heads the Upper Gastrointestinal Cancer Program at McGill University. Dr Ferri couples this clinical activity with an active translational and fundamental research program investigating the mechanisms of therapy resistance in gastro-esophageal adenocarcinoma and the inflammatory basis of cancer progression for which he is the recipient of numerous peer review grants from the Canadian Institutes of Health Research, Canadian Cancer Society, United States Department of Defense, and a Grand Challenge from Cancer Research UK.

He was appointed consultant OG surgeon at the Royal Victoria Infirmary,
Newcastle-upon-Tyne in 2001. He took up his current position in 2006, as Head of Department in Guildford, where he has built a 5-consultant lead OG team, that has pioneered minimal access surgery, enhanced recovery, pre-habilitation and more recently robotic surgery. The Unit serves a population of 4.5 million people across Surrey and Sussex. As an early adopter of Endoscopic Ultrasound, he has taught many others.
His Fellowship was at the National Cancer Center Hospital, Tokyo in 2001, improving his radical OG surgery. After visiting Professor JD Luketich, University of Pittsburgh Medical Center (UPMC) in 2006, he established a MIO programme. In 2011, with his team and Dr Don Low, Virginia Mason Medical Center, Seattle, they developed the first ERAS & Standardised Clinical Pathway for oesophageal cancer surgery in the UK.
Mr Preston’s obtained his Doctorate (University of Leeds) in 1997 and has maintained an active
interest in research. He was National Chief Investigator on the Neo-AEGIS trial, recently published in The Lancet – Gastroenterology & Hepatology (2023) and was Principal Investigator in the OCCAMS
Consortium that has vastly expanded our understanding of oesophageal and junctional
adenocarcinoma.

She is lead investigator for a Health Research and Irish Cancer Society funded research programme on nutrition in survivorship following oesophagogastric cancer surgery, including the international multicentre ENSURE study and European SARONG-II RCT. Jessie has a major interest in clinical and translational research to improve outcomes for patients with oesophagogastric cancer. Her research focuses on nutrition, survivorship and implementation of minimally invasive cancer surgery.

He performed Hong Kong’s first ESD and POEM in 2004 and 2010, respectively. In 2011 he pioneered world’s first robotic gastric ESD,
followed by first robotic colorectal ESD in 2020. He is a founding member of the Upper GI
International Robotic Association which fosters effective implementation and advancement of
robotic esophagectomy worldwide. He was bestowed Honorary Membership of the European Association of Endoscopic Surgery and Karl-Storz-Harold Hopkins Golden Telescope Award in 2023.

Dr. Pouw’s clinical work focusses on
offering a wide range of endoscopic treatments to patients with upper gastrointestinal neoplasia.
Furthermore, she supervises several research lines on endoscopic management of early Barrett’s neoplasia and endoscopic vacuum therapy for treatment of defects in the upper gastrointestinal tract.
Dr. Pouw is active as board member for several (inter-)national societies, such as Young International Society for Diseases of the Esophagus (ISDE), United European Gastroenterology (UEG), and European Society of Gastrointestinal Endoscopy (ESGE).

A graduate of the University of Southern California Medical School, Dr. Hofstetter focused on
thoracic surgical disease, completing fellowships in esophageal and foregut surgeries at the
University of Southern California, and then thoracic oncology at M. D. Anderson Cancer Center.
Broadly trained as a cardiothoracic surgeon and thoracic oncologist at the Texas Heart Institute, he
now devotes a great deal of his work to esophageal cancer and lung cancer. At M. D. Anderson, he
formed a strong network of clinicians with specific interests in esophageal diseases. A
multidisciplinary group emerged under his able leadership, and together, physicians from other
specialties like Gastrointestinal Medical Oncology, Radiation Oncology, and Gastroenterology
collaborate closely to treat esophageal cancer patients.
Dr. Hofstetter is a leading proponent of surgical and multidisciplinary approaches to esophageal
cancer and minimally invasive approaches to lung cancer, bringing to the institution his unique
clinical skills in MIS approaches to thoracic surgery.

Board certified both by the American Board of Surgery and the American Board of Thoracic Surgery,
Dr. Hofstetter is nationally and internationally involved in a host of clinical and scientific endeavors
with membership in several organizations, the Society for Surgery of the Alimentary Tract, the
General Thoracic Surgical Club, the American Association for Thoracic Surgery, including the Society
of Thoracic Surgeons, and the International Association for the Study of Lung Cancer. His research,
which forms a vital part of his academic role, has led to numerous peer-reviewed publications,
notably in such journals as the Journal of Thoracic and Cardiovascular Surgery, Annals of Thoracic
Surgery, and Cancer.

He was appointed professor of Gastrointestinal Surgery and Upper GI Surgery in 2017 at the University of Amsterdam. Mark van Berge Henegouwen, born and raised in the Netherlands, received his MD and PhD at the University of Amsterdam.

He performed his fellowship
in gastrointestinal and minimally invasive surgery at the Academic Medical Center in Amsterdam where he started as senior consultant in 2006.
His clinical practice is dedicated to patients with malignancies of the
esophagus and stomach. The Amsterdam UMC is currently one of the largest centers for esophageal and gastric cancer in Europe. The Amsterdam UMC is a tertiary referral center for these patients with around 250 esophago-gastric resections annually.

Mark van Berge Henegouwen has introduced minimally invasive and robotic surgery for esophageal and gastric cancer at his center in 2009 and now around 90 percent of patients is treated either thoraco-
laparoscopically or robotically.

Mark van Berge Henegouwen is a Principal Investigator in upper GI cancer Surgery and main research activities are focused on improvement of outcomes
in upper GI cancer surgery, outcomes in the Dutch Upper GI Cancer Audit, improvement and use of minimally invasive, robotic and fluorescence
techniques, complication management in upper GI surgery, neoadjuvant treatment regimens in esophageal and gastric cancer and quality of life in upper GI cancer surgery. He has supervised and currently supervises over 40
PhD’s and has authored over 450 peer reviewed papers and book chapters in these fields.